Legal Representation
Attorney
Monica Riva Talley
USPTO Deadlines
Next Deadline
1613 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-12-12)
Due Date
December 12, 2029
Grace Period Ends
June 12, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Dec 12, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Dec 12, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Nov 8, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Nov 7, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Aug 23, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Aug 16, 2023 | IUAF | S | USE AMENDMENT FILED |
| Aug 16, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Apr 17, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Apr 17, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Apr 17, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Mar 7, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 6, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Mar 3, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Mar 1, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Feb 17, 2023 | EXT5 | S | SOU EXTENSION 5 FILED |
| Feb 17, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 15, 2023 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Jan 11, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Aug 20, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Aug 18, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Aug 18, 2022 | EXT4 | S | SOU EXTENSION 4 FILED |
| Aug 18, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 18, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 16, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Feb 16, 2022 | EXT3 | S | SOU EXTENSION 3 FILED |
| Feb 16, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 14, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Aug 12, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Aug 12, 2021 | EXT2 | S | SOU EXTENSION 2 FILED |
| Aug 12, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 16, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 12, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Feb 12, 2021 | EXT1 | S | SOU EXTENSION 1 FILED |
| Feb 12, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 18, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Jul 9, 2020 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS |
| Jul 9, 2020 | OP.D | T | OPPOSITION DISMISSED NO. 999999 |
| Jul 9, 2020 | OP.T | T | OPPOSITION TERMINATED NO. 999999 |
| Jun 10, 2020 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Oct 23, 2019 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Oct 23, 2019 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Feb 27, 2019 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 |
| Nov 28, 2018 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Oct 30, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Oct 30, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Oct 10, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Sep 21, 2018 | ALIE | A | ASSIGNED TO LIE |
| Sep 6, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 31, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Aug 30, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Detailed Classifications
Class 005
Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), frontotemporal dementia, cognitive impairment of aging, pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, chronic neuropathic pain, peripheral neuropathy, pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, Obsessive Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, adjunctive use
First Use Anywhere:
20230700
First Use in Commerce:
20230700
Classification
International Classes
005
USPTO Documents
Click to view cached USPTO documents for this trademark
Only administrators can request new documents from USPTO